BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38303345)

  • 1. [Minimally Invasive Conversion Hepatectomy for Advanced Hepatocellular Carcinoma].
    Sakai H; Goto Y; Shimose S; Niizeki T; Kawaguchi T; Akiba J; Yano H; Akagi Y; Fujita F; Hisaka T
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1572-1574. PubMed ID: 38303345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
    Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
    Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protocol of the RACB study: a multicenter, single-arm, prospective study to evaluate the efficacy of resection of initially unresectable hepatocellular carcinoma with atezolizumab combined with bevacizumab.
    Okuno M; Ishii T; Ichida A; Soyama A; Takemura N; Hirono S; Eguchi S; Hasegawa K; Sasaki Y; Uemura K; Kokudo N; Hatano E
    BMC Cancer; 2023 Aug; 23(1):780. PubMed ID: 37605169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role and limitation of neoadjuvant hepatic arterial infusion chemotherapy in advanced hepatocelluar carcinoma patients with Child-Pugh class A.
    Lee BH; Lee DS; Cho CW; Yun SS
    World J Surg Oncol; 2019 Aug; 17(1):143. PubMed ID: 31416447
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Kakizaki S; Shimada N; Kawata K; Naganuma A; Kosaka H; Shibata H; Aoki T; Tanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Kaibori M; Hiasa Y; Kudo M;
    Cancer Med; 2023 Jan; 12(1):325-334. PubMed ID: 35666040
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of curative conversion therapy aimed at a cancer-free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab.
    Shimose S; Iwamoto H; Shirono T; Tanaka M; Niizeki T; Kajiwara M; Itano S; Yano Y; Matsugaki S; Moriyama E; Noda Y; Nakano M; Kuromatsu R; Koga H; Kawaguchi T
    Cancer Med; 2023 Jun; 12(11):12325-12335. PubMed ID: 37062077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
    Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
    Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion surgery for hepatocellular carcinoma with portal vein tumor thrombus after successful atezolizumab plus bevacizumab therapy: a case report.
    Hidaka Y; Tomita M; Desaki R; Hamanoue M; Takao S; Kirishima M; Ohtsuka T
    World J Surg Oncol; 2022 Jul; 20(1):228. PubMed ID: 35831894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pathological complete response of hepatocellular carcinoma confirmed by conversion hepatectomy following atezolizumab plus bevacizumab therapy: a case report and literature review.
    Sato S; Aoki T; Matsumoto T; Shiraki T; Mori S; Iso Y; Nemoto T; Onishi T; Iijima M; Ishida K
    Clin J Gastroenterol; 2024 Apr; 17(2):292-299. PubMed ID: 38071671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathological complete response by advanced hepatocellular carcinoma with massive macrovascular invasion to hepatic arterial infusion chemotherapy: a case report.
    Sano S; Nakata S; Wada S; Kuroiwa M; Sakai H; Kusama K; Machida T; Nishio A; Ito I; Sodeyama H
    World J Surg Oncol; 2019 Dec; 17(1):229. PubMed ID: 31878937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Objective Response and Progression-Free Survival Contribute to Prolong Overall Survival in Atezolizumab plus Bevacizumab Treatment for Unresectable Hepatocellular Carcinoma.
    Tajiri K; Tsukada K; Tokimitsu Y; Motofuji Y; Kawai K; Muraishi N; Murayama A; Hayashi Y; Shimizu Y; Yasuda I
    Oncology; 2024; 102(2):131-140. PubMed ID: 37666216
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison Between Portal Vein Perfusion Chemotherapy and Neoadjuvant Hepatic Arterial Infusion Chemotherapy for Resectable Intermediate to Advanced Stage Hepatocellular Carcinoma.
    Pan Y; Mei J; Chen J; Zhang D; Wang J; Wang X; Yi M; Zhou Z; Zhang Y; Chen M; Guo R; Xu L
    Ann Surg Oncol; 2022 Mar; 29(3):2016-2029. PubMed ID: 34637058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative Chemotherapy Followed by Hepatectomy for Potentially Resectable UICC7 Stage IIIA, IIIB Hepatocellular Carcinoma; A Phase II Clinical Trial.
    Goto Y; Niizeki T; Fukutomi S; Shirono T; Shimose S; Iwamoto H; Kojima S; Kanno H; Uchino Y; Sasaki S; Shirahama N; Muroya D; Nomura Y; Akashi M; Nakayama G; Hirakawa Y; Sato T; Yoshitomi M; Sakai H; Hisaka T; Kakuma T; Koga H; Torimura T; Akagi Y; Okuda K
    Kurume Med J; 2023 Sep; 68(3.4):239-245. PubMed ID: 37518005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatic Resection Followed by Hepatic Arterial Infusion Chemotherapy for Hepatocellular Carcinoma with Intrahepatic Dissemination.
    Kuramoto K; Beppu T; Nitta H; Imai K; Masuda T; Miyata T; Koga Y; Kitano Y; Kaida T; Nakagawa S; Okabe H; Hayashi H; Hashimoto D; Yamashita YI; Chikamoto A; Kikuchi K; Baba H
    Anticancer Res; 2018 Jan; 38(1):525-531. PubMed ID: 29277819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advanced hepatocellular carcinoma with hepatic vein tumor thrombosis and renal dysfunction after hepatic arterial infusion chemotherapy effectively treated by liver resection with active veno-venous bypass: report of a case.
    Itoh A; Sadamori H; Yabushita K; Monden K; Tatsukawa M; Hioki M; Hyodo T; Omonishi K; Ueki T; Ohno S; Sakaguchi K; Takakura N
    BMC Cancer; 2016 Sep; 16(1):705. PubMed ID: 27586890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.
    Arita J; Ichida A; Nagata R; Mihara Y; Kawaguchi Y; Ishizawa T; Akamatsu N; Kaneko J; Hasegawa K
    J Hepatobiliary Pancreat Sci; 2022 Jul; 29(7):732-740. PubMed ID: 35306748
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
    Iwamoto H; Shimose S; Shirono T; Niizeki T; Kawaguchi T
    Clin Mol Hepatol; 2023 Jul; 29(3):593-604. PubMed ID: 36775834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab.
    Yano S; Kawaoka T; Johira Y; Miura R; Kosaka M; Shirane Y; Murakami S; Amioka K; Naruto K; Ando Y; Kosaka Y; Yamaoka K; Kodama K; Uchikawa S; Fujino H; Ohno A; Nakahara T; Murakami E; Okamoto W; Yamauchi M; Imamura M; Mori K; Arihiro K; Kuroda S; Kobayashi T; Ohdan H; Aikata H
    Medicine (Baltimore); 2021 Oct; 100(42):e27576. PubMed ID: 34678902
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A case of conversion hepatectomy for huge hepatocellular carcinoma with adrenal metastasis and vascular invasion after atezolizumab-bevacizumab treatment.
    Hoshino T; Naganuma A; Furusawa A; Suzuki Y; Hirai K; Sakamoto I; Ogawa T; Ogawa A; Hatanaka T; Kakizaki S
    Clin J Gastroenterol; 2022 Aug; 15(4):776-783. PubMed ID: 35585285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.